Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis

2015 International journal of clinical and experimental 8;10 (17654-17663)

AIM: to evaluate the performance and accuracy of Controlled attenuation parameter CAP for hepatic steatosis detection. METHODS: PubMed, EBSCO, Elsevier Science, Ovid, and Wiley were selected to search studies until August 31, 2014. Quality Assessment of Diagnostic Accuracy Studies checklist was used to assess the quality of included studies. Heterogeneity was evaluated using Q test. Sensitivity, specificity, diagnostic odds ratio (DOR), and the area under curve (AUC) with its 95% confidence intervals (CIs) were calculated to evaluate the accuracy of CAP for assessment of hepatic steatosis stage (>/= S1, >/= S2 and >/= S3). RESULTS: Totally 11 studies (13 cohorts) with high methodological qualities were identified. The summary point estimations with 95% CIs of sensitivity, specificity, AUC and DORs were 0.78 (0.71, 0.84), 0.79 (0.70, 0.86), 0.86 (0.82, 0.88), and 14 (7, 27) for >/= S1; 0.82 (0.74, 0.88), 0.79 (0.73, 0.85), 0.88 (0.85, 0.90) and 18 (10, 30) for >/= S2; 0.86 (0.82, 0.89), 0.89 (0.86, 0.92), 0.94 (0.91, 0.96) and 51 (35, 76) for >/= S3. Significant heterogeneity was found among the studies in >/= S1 and >/= S3. Threshold effect was existed in >/= S3, but not in >/= S1 and >/= S2. Publication bias was not existed in >/= S1 and >/= S2 except >/= S3. CONCLUSION: CAP provides good sensitivity and specificity for detection of >/= S1, >/= S2, and >/= S3 steatosis. However, future studies with large samples are still necessary to confirm the clinical application.

Pubmed : 26770355